Sysmex Europe
Menu

Collaboration of Medicaroid, Kawasaki Heavy Industries and Sysmex for the business of the“hinotori TM Surgical Robot System”, a robotic assisted surgery system

Medicaroid Corporation (HQ: Kobe; President: Kaoru Asano; hereinafter referred to as Medicaroid) announces the Japanese regulatory approval for the hinotoriTM Surgical Robot System. Consequently, Medicaroid is planning to strongly promote the business activities associated with the robotic assisted surgery system under the support of its investing companies: Kawasaki Heavy Industries Inc. (HQ: Kobe, President: Yasuhiko Hashimoto; hereinafter referred to as Kawasaki Heavy Industries) and Sysmex Corporation (HQ: Kobe; President: Hisashi Ietsugu; hereinafter referred to as Sysmex), and make a contribution to the development and evolution of healthcare.

Background

In 2013, Medicaroid was jointly established as a commercial company for medical robot development, by Kawasaki Heavy Industries, a leading company of industrial robots, and Sysmex Corporation, an experienced business player which has expertise in inspection and diagnosis and an extensive network in the medical field.From 2015, Medicaroid entered the full-scale product development stage,so Kawasaki Heavy Industries and Sysmex have made additional investments in Medicaroid to smoothly promote the development. In addition to the investment, utilization of Kawasaki Heavy Industries' technology and know-how of industrial robots and Sysmex's technology and know-how of inspection and diagnostic in the medical field supportedthe development of surgical robots, which contributed to launch of the hinotoriTM Surgical Robot System.

Role of Medicaroid

Medicaroid is responsible for marketing the hinotoriTM Surgical Robot System. Together with Kawasaki Heavy Industries, Medicaroid manufactures the hinotoriTM Surgical Robot System and the instruments, and develops and manufactures new instruments to expand the applicable indications for use. In collaboration with Sysmex, Medicaroid will sell the hinotoriTM Surgical Robot System and the instruments and provide services and support to medical staff (including network services and supportusing IoT).

 

Role of Kawasaki Heavy Industries

In 1969, Kawasaki Heavy Industries succeeded in domestically producing Japan's first industrial robot. Since then, along with the development of Japanese manufacturing, they have provided high-quality and high-performance robotsand high-value-added solutions to various industries as a pioneer of industrial robots.In Medicaroid's surgery support robot system business, Kawasaki Heavy Industries has jointly developed the hinotoriTM Surgical Robot System andtheinstruments, leveraging the technology and know-how of industrial robots. Going forward, Kawasaki Heavy Industries will support the manufacture of the hinotoriTM Surgical Robot System and the development of new instruments to expand the applicable indications for use. They will also support the maintenance work for the system and the instruments.

Role of Sysmex

Sysmex has an integrated operation system from R&D, manufacturing, sales to services and supportof medical device, reagents and software for in-vitro testing. They deliver their products to medical institutions in more than 190 countries and regions.Also,in Medicaroid's business for the robotic assisted surgery system, Sysmex will deliver the hinotoriTM Surgical Robot System and the instruments to medical professionals as a general agent of Medicaroid products. Concurrently, Sysmex will develop network services and support content for efficient surgery while ensuring safety and creating environments for the entire operating room.

By combining Kawasaki Heavy Industries’and Sysmex's technology and know-how with Medicaroid's technology and experience in medical robot development, the companies are committed to contributing to a prosperous society where everyone, including patients, their families and healthcare workers, can live with peace of mind.

 

Product Outline

JMDN: Surgical robot unit
Sales name:hinotoriTM Surgical Robot System (Approval number: 0200BZX00256000) HF series instruments (Approval number:30200BZX00257000)
Target market: Japan and overseas (International sales will start after regulatory approval and license for each country)
Manufacturer: Medicaroid Corporation

Company Outline

Name: Medicaroid Corporation

Location: International Medical Device Alliance 6th Floor, 1-6-5 Minatojima Minami-machi, Chuo-ku, Kobe 650-0047, Japan
Establishment:August 29, 2013Capital:¥7.96 billion (as of December 31, 2019)
Ownership: Kawasaki Heavy Industries: 50%; Sysmex Corporation: 50%
Representative:

  • President: Kaoru Asano
  • Executive Vice President, Member of the Managing Board: Hirofumi Tanaka

Lines of business: Marketing, development, design, manufacturing, sales, and after-sales-service related to medical robots

 

Reference

Press release on August 11, 2020Medicaroid received Japanese regulatory approvalforthe“hinotoriTMSurgical Robot System”, as the first made-in-Japan robotic assisted surgery system.http://www.medicaroid.com/en/release/pdf/20200811-1_en.pdf

 

Back to overview
Copyright © Sysmex Europe GmbH. All rights reserved.
Customize your experience

We use cookies to enable you to optimally use our Website and to improve our communication with you. We shall take your selection into account and use only the data for which you give us your consent.

* May lead to restrictions in content and in the user experience
Detail about cookies
Essential cookies
These cookies help to make our website usable by enabling basic features such as page navigation and access to secure areas of our website. Our website cannot function properly without these cookies.
Statistics cookies
By collecting information anonymously, these cookies help us to understand how visitors interact with our website. This information enables us to continually improve our platform.
Marketing cookies
are used to track visitors on websites. The intention is to show advertisements that are relevant and appealing to the individual user and are, therefore, valuable to publishers and third-party advertisers.